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Introduction
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder that encompasses three syndromes previously considered to be separate disorders:
striatonigral degeneration, olivopontocerebellar atrophy, and Shy-Drager syndrome.
According to a consensus statement on MSA diagnosis, predominately parkinsonian features are associated with the MSA-P subtype, whereas predominately cerebellar features are associated with the MSA-C subtype [1] . Although the cause of MSA is still unknown, genetic and immunohistological evidence suggests that oxidative stress contributes to MSA pathogenesis [2] [3] [4] .
Previous studies indicate that uric acid (UA) can protect neurons against neurodegeneration by exerting antioxidative effects. For instance, a higher serum UA concentration reduces the risk of Parkinson's disease onset and slows progression of the disease [5, 6] , and the serum UA concentration is linked to the progression of other neurodegenerative disorders such as Huntington's disease and amyotrophic lateral sclerosis [7, 8] . However, the role of UA in MSA is not well understood. Although some previous studies reported that the serum UA concentration was not associated with MSA progression or survival [9, 10] , others reported that the serum UA concentration was correlated with MSA occurrence and progression [10] [11] [12] . Therefore, we examined Fukae J et al.
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whether the serum UA concentration was linked to disease progression in MSA patients.
Material and Methods

Subjects
A total of 53 Japanese MSA patients were enrolled in this study. These patients were admitted, and their clinical symptoms were evaluated in the Department of Neurology, Fukuoka University Hospital or Juntendo University Hospital between January 2009 and March 2015. MSA was diagnosed according to the second consensus criteria [13] , and all patients enrolled in this study had clinically probable MSA. The enrolled patients were all inpatients at baseline, and diagnosis of MSA was confirmed by more than two expert neurologists. Key exclusion criteria were severe dementia, psychiatric symptoms, and severe complications such as pneumonia, bone fracture, and advanced-stage cancer. The study was approved by the Fukuoka University and Juntendo University committees for medical research ethics and followed the principles outlined in the Declaration of Helsinki.
Blood samples for laboratory analysis including the serum UA concentration were obtained from all subjects between 5:00-7:00 am, following about 8 hours of fasting. Venous blood samples (9 ml) were taken from each MSA patient, and then serum was separated within the hour by centrifugation at 3,500 rpm for 6 min. The serum UA concentration was measured with enzymatic methods (Labospect008, Hitachi, Tokyo, Japan). To evaluate the general condition, the following data were retrospectively obtained from all subjects by inquiry and physical and laboratory examinations: age, sex, history of hypertension and diabetes mellitus, body mass index (BMI, kg/m 2 ), total cholesterol (T-cho; mg/dL), low-density lipoprotein cholesterol (LDL-C; mg/dL), and triglycerides (TG; mg/dL).
Assessment of MSA
The clinical severity of MSA was evaluated with the global disability scale (GDS) in the Unified Multiple System Atrophy Rating Scale (UMSARS part IV) [14] . The information about MSA patients, such as the UA concentration and disease duration,
was not disclosed to evaluators of GDS. The average disease progression rate was defined as a GDS (UMSARS part IV) change per one year, which was calculated using the following formula:
Disease progression rate = GDS (UMSARS part IV)/disease duration (years)
Data analysis
Statistical analyses were performed using SPSS software package version 21 (SPSS Inc., Chicago, IL, USA) for Macintosh. The UA concentrations of all subjects were divided into tertiles to minimize the influence of any extreme observation on the results (group 1, low UA concentration: ≤4.0 mg/dL; group 2, moderate UA concentration: 4.1-5.0 mg/dL; group 3, high UA concentration: ≥5.1 mg/dL). Differences in clinical and demographic characteristics were evaluated using Fisher's exact test and one-way analysis of variance. To evaluate the trend in the mean average disease progression rate by groups, the Jonckheere-Terpstra trend test was performed. In addition, the 
Results
Clinical, laboratory, and medication data for each group of MSA patients are presented in To evaluate the correlations between disease progression and the serum UA concentration, we performed Spearman's correlation analysis. In all subjects, the serum UA concentration showed a mild inverse correlation with average disease progression Adjusted ORs for rapid disease progression after adjusting for other potential confounders are shown in Table 2 . When patients were divided by sex, the association between the UA group and the average disease progression rate was significant only among males (ORs of high UA concentration, 0.021; 95% CI, 0.001-0.704; p = 0.031).
In addition, BMI (OR 0.637, 95% CI, 0.452-0.897, p = 0.01) was independently associated with rapid disease progression. Other covariates including the daily levodopa dose were not associated with rapid disease progression in MSA patients.
Discussion
In this retrospective study, we found that the serum UA concentration was inversely associated with disease progression in male MSA patients. In addition, multivariable logistic regression analysis demonstrated that the OR of rapid disease progression in the highest serum UA group was significantly lower than that in the lowest serum UA group only in male patients with MSA.
Patients with MSA show various symptoms, and several previous clinical studies have reported associations between disease occurrence, disease progression, survival, and cognitive function in MSA patients and the serum UA concentration [9] [10] [11] [12] 15] . Two cross-sectional studies demonstrated that the occurrence of MSA was decreased in patients with a high UA concentration, especially in male patients [10, 12] .
Regarding the link between survival and the serum UA concentration in MSA patients, Kim et al. found no association between survival and serum UA in MSA patients [9] .
Another report demonstrated that the UA concentration is inversely associated with cognitive deficits in MSA patients [15] .
Two previous reports investigated disease progression and the serum UA concentration in MSA patients. These two reports showed different conclusions. First, a prospective study evaluated the influence of the serum UA concentration on disease progression in 52 MSA patients [11] and concluded that the serum UA concentration was inversely correlated with motor symptom changes. A second report revealed that the serum UA concentration is not associated with MSA progression [10] . However, they also stated that patients with severe symptoms at baseline had a lower rate of return visits. Our study suggested a significant correlation between the serum UA concentration and disease progression in the early stage with less than three years of disease duration. This result suggested that the antioxidative functions of UA may be more effective in mild neurodegeneration, and the antioxidative effect of UA may be less apparent after severe neurodegeneration has occurred.
The hallmark histopathological finding of MSA is the appearance of glial cytoplasmic inclusions (GCIs) [16] . GCIs include alpha-synuclein, which is associated with neuronal death. Previous quantitative analysis revealed a positive correlation between neuronal loss and GCI density, suggesting that accumulation of GCIs is likely to be an important factor in neuronal degeneration in MSA [16] . Oxidative stress promotes extracellular alpha-synuclein uptake in oligodendrocytes and alpha-synuclein oligomer formation and aggregation [17] , indicating that oxidative stress may promote formation of GCIs. Because UA decreases oxidative stress by removing superoxide, hydroxyl radicals, and singlet oxygen [18] , the antioxidative effects of UA may inhibit formation of GCIs.
Growing evidence suggests that oxidative stress is associated with the pathogenesis of MSA. Recently, mutations in the COQ2 have been discovered in families in Japan with autosomal-recessive MSA [2] . Moreover, a polymorphism in the COQ2 (p. V343A) is significantly associated with sporadic MSA patients compared with control subjects [2] . COQ2 is an enzyme that is essential for biogenesis of coenzyme Q10 (coQ10). CoQ10 is an essential cofactor for electron transport in the mitochondrial respiratory chain. Impaired COQ2 activity may induce mitochondrial dysfunction and increase oxidative stress.
Our results suggested that serum UA may be associated with disease progression in only male patients with MSA. Previous studies have reported that male Parkinson's disease patients with a higher UA concentration show slower rates of clinical decline [5, 6] . A neuroprotective effect of UA was obvious at a level above 6 mg/dL [5, 6, 19] .
Consistent with these studies, our results showed that only male MSA patients with a high UA concentration (i.e., >5.5 mg/dL) exhibited slower disease progression. Our results may support previous reports that suggested that the neuroprotective effect of UA increases in a dose-dependent manner in neurodegenerative diseases [5, 6] . Because males typically have higher serum UA concentrations than females, the antioxidative effects of UA are more likely to be seen in males. Furthermore, estrogen has neuroprotective effects [21] and may affect progression in female MSA patients.
Therefore, disease progression may be not associated with UA in female MSA patients.
Our study has several limitations. First, this study was retrospective, and the UA concentration at disease onset was unknown. Second, the severity of MSA was evaluated with GDS. A validation study of UMSARS demonstrated that GDS (UMSARS part IV) is well correlated with UMSARS part I and part II and the Schwab and England Activities of Daily Living scale [22] [23] [24] , suggesting that GDS (UMSARS part IV) is a sensitive scale for assessing activities of daily living and motor function in patients with MSA. UMSARS part I is used to evaluate the ability of patients to perform activities of daily living, and part II assesses motor functions such as alternative movements, muscle tone, gait, and posture, as well as involuntary movements. Part III is used to evaluate autonomic functions. We did not score UMSARS part I, II, or III in our patients; therefore, we could not evaluate a relationship between the serum UA concentration and progression of various symptoms in MSA. Further studies are needed to address the relationship between the serum UA concentration and disease progression utilizing UMSARS part I, II, III, and IV. Third, accurate assessment of disease duration was needed in this study. The cognitive impairment in these patients hindered our ability to collect accurate information; therefore, MSA patients with severe dementia were excluded from this study. Moreover, information about MSA such as the UA concentration and disease duration affects evaluation of GDS. Therefore, evaluation of GDS and collection of information about MSA were performed by different clinicians to avoid bias.
In conclusion, our study demonstrated that MSA patients with a higher serum UA concentration showed slower disease progression, especially in male patients. The serum UA concentration showed a mild negative correlation with average disease progression in all subjects. For sex, we observed a significant correlation between the serum UA concentration and average disease progression only in male patients. PR: progression rate; UA: uric acid (mg/dL).
